Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk
- PMID: 40665102
- DOI: 10.1007/s12072-025-10874-8
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk
References
-
- Kim JY, Kim H, Yoo JJ, Kim SG, Kim YS. Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis. Hepatol Int 2025. https://doi.org/10.1007/s12072-025-10809-3 - DOI - PubMed
-
- Hsu PY, Su HC, Ma MC, Chen CA, Yu SY, Hua YM. Impact of tenofovir alafenamide on lipid profiles in chronic hepatitis B patients: systematic review and meta-analysis. J Med Virol 2025;97(4): e70331 - PubMed
-
- Cheng PN, Feng IC, Chen JJ, Kuo HT, Lee PL, Yu ML, et al. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Aliment Pharmacol Ther 2024;59(2):230–238 - PubMed
-
- Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, et al. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol 2021;56(2):168–180 - PubMed
Publication types
LinkOut - more resources
Full Text Sources